Physician profile
Edward S Smith
NPI 1679577100
$2,165.22
in general payments reported to CMS, 2019-2025
17 companies · $390 in 2025
The $390 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $65.63 · 2021: $99.63 · 2022: $148 · 2023: $583 · 2024: $423 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,201 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,200.72 |
| Education | $195.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $755.25 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $380.39 | 2019-2024 | Tremfya |
| Genzyme Corporation | $216.08 | 2022-2025 | |
| Amgen INC. | $164.75 | 2021-2023 | Otezla |
| Catalyst Pharmaceuticals, INC. | $157.46 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $103.10 | 2019 | |
| Celgene Corporation | $92.98 | 2019 | |
| Ucb, INC. | $59.50 | 2025 | Bimzelx |
| Dermavant Sciences, INC. | $50.66 | 2022-2023 | Vtama |
| Novartis Pharmaceuticals Corporation | $41.52 | 2020-2023 | |
| Arcutis Biotherapeutics, INC. | $39.42 | 2024 | Zoryve |
| Pfizer INC. | $30.54 | 2023-2024 | |
| Biofrontera INC. | $21.47 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $18.54 | 2024 | Sotyktu |
| Galderma Laboratories, L.P. | $17.33 | 2025 | Nemluvio |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $12.08 | 2022 | |
| Prugen, INC. Pharmaceuticals | $4.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.